In addition, we could not detect any significant changes in the amount of antiapoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in the cisplatin/LA-12 and TRAIL combination-treated prostate cancer cells. This evidence concerns the gene BCL2 and prostate carcinoma.